Market Research Report
Europe DIABETES DRUGS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||618294|
|Published||Content info||66 Pages
Delivery time: 1-2 business days
|Europe DIABETES DRUGS MARKET FORECAST 2018-2026|
|Published: April 9, 2018||Content info: 66 Pages||
The Europe diabetes drug market is expected to progress with a 5.08% CAGR over the forecast years of 2018-2026. It is the second largest market for diabetes drugs.
An increase in life-expectancy and growing prevalence of diabetes in the population are factors driving growth in the European diabetes drug market. The development of new formulations and increasing research and development are factors presenting the market with lucrative growth opportunities. However, fierce market competition and rising concerns in scientific community could restrain the market expansion.
Some of the well-known diabetes drug manufacturing companies include AstraZeneca Plc, GlaxoSmithKline, Xeris Pharmaceuticals, Eli Lilly And Company, B.Braun Melsungen Ag, Novo Nordisk A/S, Pfizer, Albireo Pharma Inc, Macrogenics Inc, Astellas and Merck.